TABLE 2

Incidence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection up to 31 December 2020 in people with cystic fibrosis (pwCF) by lung transplant status and by age group

Age group years	All			Non-lung transplant			Lung transplant
Age group years	Cases	CF population	Incidence per 1000 (95% CI)	Cases	CF population	Incidence per 1000 (95% CI)	Cases	CF population	Incidence per 1000 (95% CI)
Total	828	48 211	17.2 (16.0–18.4)	750	45 266	16.6 (15.4–17.8)	78	2729	28.6 (22.7–35.5)
0–11	134	17 179	7.8 (6.5–9.2)	134	17 100	7.8 (6.6–9.3)	0	13	0.0 (0.0–247.1)
12–17	113	7396	15.3 (12.6–18.3)	111	7278	15.3 (12.6–18.3)	2	84	23.8 (2.9–83.4)
18–29	291	12 162	23.9 (21.3–26.8)	268	11 286	23.7 (21.0–26.7)	23	816	28.2 (17.9–42)
30–39	164	6493	25.3 (21.6–29.4)	135	5445	24.8 (20.8–29.3)	29	1014	28.6 (19.2–40.8)
40–49	87	3280	26.5 (21.3–32.6)	67	2679	25.0 (19.4–31.7)	20	583	34.3 (21.1–52.5)
≥50+	39	1701	22.9 (16.4–31.2)	35	1478	23.7 (16.5–32.8)	4	219	18.3 (5.0–46.1)

All cases of SARS-CoV-2 in pwCF and the general population were PCR-confirmed. Incidence was calculated as (SARS-CoV-2 cases/number of people in the population) × 1000. CF population size was from the 2018 European Cystic Fibrosis Society Patient Registry report (2017 for France).